Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration
Cell Reports, ISSN: 2211-1247, Vol: 23, Issue: 3, Page: 808-822
2018
- 127Citations
- 136Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations127
- Citation Indexes127
- 127
- CrossRef42
- Captures136
- Readers136
- 136
- Mentions1
- News Mentions1
- 1
Most Recent News
Platelet-Based Nanoparticles with Stimuli-Responsive for Anti-Tumor Therapy
Introduction After the discovery of platelets in 1865, these anucleated cells once regarded as metabolic fragments of megakaryocytes, have progressively emerged as a compelling subject
Article Description
Tumor cells initiate platelet activation leading to the secretion of bioactive molecules, which promote metastasis. Platelet receptors on tumors have not been well-characterized, resulting in a critical gap in knowledge concerning platelet-promoted metastasis. We identify a direct interaction between platelets and tumor CD97 that stimulates rapid bidirectional signaling. CD97, an adhesion G protein-coupled receptor (GPCR), is an overexpressed tumor antigen in several cancer types. Purified CD97 extracellular domain or tumor cell-associated CD97 stimulated platelet activation. CD97-initiated platelet activation led to granule secretion, including the release of ATP, a mediator of endothelial junction disruption. Lysophosphatidic acid (LPA) derived from platelets induced tumor invasiveness via proximal CD97-LPAR heterodimer signaling, coupling coincident tumor cell migration and vascular permeability to promote transendothelial migration. Consistent with this, CD97 was necessary for tumor cell-induced vascular permeability in vivo and metastasis formation in preclinical models. These findings support targeted blockade of tumor CD97 as an approach to ameliorate metastatic spread.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2211124718304534; http://dx.doi.org/10.1016/j.celrep.2018.03.092; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85045083294&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/29669286; https://linkinghub.elsevier.com/retrieve/pii/S2211124718304534; https://dx.doi.org/10.1016/j.celrep.2018.03.092
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know